E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group

Journal of Clinical Oncology

Volumn 35, Issue 5, 2017, Pages 490-497

  Marur, Shanthi ^a   Li, Shuli ^b   Cmelak, Anthony J ^c   Gillison, Maura L ^d   Zhao, Weiqiang J ^d   Ferris, Robert L ^e   Westra, William H ^a   Gilbert, Jill ^c   Bauman, Julie E ^e   Wagner, Lynne I ^f   Trevarthen, David R ^g   Balkrishna, Jahagirdar ^h   Murphy, Barbara A ^c   Agrawal, Nishant ⁱ   Colevas, A Dimitrios ^j   Chung, Christine H ^k   Burtness, Barbara ^l  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g Colorado Cancer Research Program ^*  (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j STANFORD UNIVERSITY   (United States)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^l YALE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; PACLITAXEL; PROTEIN P16; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL EVALUATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; FOLLOW UP; GASTROESOPHAGEALL ADENOCARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HYPOMAGNESEMIA; INDUCTION CHEMOTHERAPY; INFECTION; INFUSION RELATED REACTION; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; LUNG ADENOCARCINOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; NON MELANOMA SKIN CANCER; NUTRITIONAL STATUS; OROPHARYNX SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PATIENT-REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DERMATITIS; RADIATION DOSE REDUCTION; RASH; SECOND CANCER; SEPSIS; SMOKING; SURVIVAL RATE; THROMBOEMBOLISM; TINNITUS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; WART VIRUS; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPLICATION; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; PHYSIOLOGY; PROCEDURES; RADIOTHERAPY DOSAGE; REMISSION; SQUAMOUS CELL CARCINOMA; VIROLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NEUTROPENIA; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; RADIOTHERAPY DOSAGE; REMISSION INDUCTION;

EID: 85012216644     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.3300     Document Type: Article

References (30)

1. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al: Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31:4550-4559, 2013
2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294-4301, 2011
3. Marur S, D'Souza G, Westra WH, et al: HPV-associated head and neck cancer: A virus-related cancer epidemic. Lancet Oncol 11:781-789, 2010
4. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261-269, 2008
5. Cmelak AJ, Li S, Goldwasser MA, et al: Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 25:3971-3977, 2007
6. Nguyen-Tan PF, Zhang Q, Ang KK, et al: Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: Longterm report of efficacy and toxicity. J Clin Oncol 32:3858-3866, 2014
7. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
8. O'Sullivan B, Huang SH, Siu LL, et al: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 31:543-550, 2013
9. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
10. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al: Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770-3776, 2008
11. Forastiere AA, Zhang Q, Weber RS, et al: Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845-852, 2013
12. Vlacich G, Spratt DE, Diaz R, et al: Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. Radiother Oncol 110:435-440, 2014
13. Diaz R, Jaboin JJ, Morales-Paliza M, et al: Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 77:468-476, 2010
14. Eisbruch A, Schwartz M, Rasch C, et al: Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 60:1425-1439, 2004
15. Vermorken JB, Trigo J, Hitt R, et al: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177, 2007
16. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
17. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654, 2005
18. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
19. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010
20. Rosenthal DI, Harari PM, Giralt J, et al: Association of human papillomavirus and p16 status with outcomes in the IMCL-9815phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab. J Clin Oncol 34:1300-1308, 2016
21. Kies MS, Holsinger FC, Lee JJ, et al: Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial. J Clin Oncol 28:8-14, 2010
22. Wanebo HJ, Lee J, Burtness BA, et al: Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: A phase II ECOG-ACRIN trial (E2303). Ann Oncol 25:2036-2041, 2014
23. Argiris A, Heron DE, Smith RP, et al: Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 28:5294-5300, 2010
24. Beetz I, Steenbakkers RJ, Chouvalova O, et al. The QUANTEC criteria for parotid gland dose and their efficacy to prevent moderate to severe patient-rated xerostomia. Acta Oncol 2014; 53:597-604.
25. Urba S, Wolf G, Eisbruch A, et al: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 24: 593-598, 2006
26. Worden FPI, Kumar B, Lee JS, et al: Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. J Clin Oncol 26:3138-3146, 2008
27. Jordan RC, Lingen MW, Perez-Ordonez B, et al: Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36:945-954, 2012
28. Egloff AM, Lee JW, Langer CJ, et al: Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern Cooperative Oncology Group trial E3303. Clin Cancer Res 20: 5041-5051, 2014
29. Cooperstein E, Gilbert J, Epstein JB, et al: Vanderbilt Head and Neck Symptom Survey version 2.0: Report of the development and initial testing of a subscale for assessment of oral health. Head Neck 34:797-804, 2012
30. Haddad R, O'Neill A, Rabinowits G, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol 14:257-264, 2013